374 related articles for article (PubMed ID: 30365112)
1. Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor.
Liu Z; Wang F; Tang M; Zhao Y; Wang X
Int J Mol Med; 2019 Jan; 43(1):435-442. PubMed ID: 30365112
[TBL] [Abstract][Full Text] [Related]
2. Hypocretin/Orexin, Sleep and Alzheimer's Disease.
Dauvilliers Y
Front Neurol Neurosci; 2021; 45():139-149. PubMed ID: 34052817
[TBL] [Abstract][Full Text] [Related]
3. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.
Wang C; Holtzman DM
Neuropsychopharmacology; 2020 Jan; 45(1):104-120. PubMed ID: 31408876
[TBL] [Abstract][Full Text] [Related]
4. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation.
Angulo E; Casadó V; Mallol J; Canela EI; Viñals F; Ferrer I; Lluis C; Franco R
Brain Pathol; 2003 Oct; 13(4):440-51. PubMed ID: 14655750
[TBL] [Abstract][Full Text] [Related]
5. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease.
Roh JH; Jiang H; Finn MB; Stewart FR; Mahan TE; Cirrito JR; Heda A; Snider BJ; Li M; Yanagisawa M; de Lecea L; Holtzman DM
J Exp Med; 2014 Dec; 211(13):2487-96. PubMed ID: 25422493
[TBL] [Abstract][Full Text] [Related]
6. Selective orexin 1 receptor antagonist SB-334867 aggravated cognitive dysfunction in 3xTg-AD mice.
Gao WR; Hu XH; Yu KY; Cai HY; Wang ZJ; Wang L; Wu MN
Behav Brain Res; 2023 Feb; 438():114171. PubMed ID: 36280008
[TBL] [Abstract][Full Text] [Related]
7. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.
Liguori C; Romigi A; Nuccetelli M; Zannino S; Sancesario G; Martorana A; Albanese M; Mercuri NB; Izzi F; Bernardini S; Nitti A; Sancesario GM; Sica F; Marciani MG; Placidi F
JAMA Neurol; 2014 Dec; 71(12):1498-505. PubMed ID: 25322206
[TBL] [Abstract][Full Text] [Related]
8. Orexin and Alzheimer's Disease.
Liguori C
Curr Top Behav Neurosci; 2017; 33():305-322. PubMed ID: 28012089
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
10. Diurnal Characteristics of the Orexin System Genes and Its Effects on Pathology at Early Stage in 3xTg-AD Mice.
Yin J; Tuo CM; Yu KY; Hu XH; Fan YY; Wu MN
Neuromolecular Med; 2023 Dec; 25(4):632-643. PubMed ID: 37843792
[TBL] [Abstract][Full Text] [Related]
11. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Aβ and pTau in a mouse model of Alzheimer's disease.
Rothman SM; Herdener N; Frankola KA; Mughal MR; Mattson MP
Brain Res; 2013 Sep; 1529():200-8. PubMed ID: 23856323
[TBL] [Abstract][Full Text] [Related]
12. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
13. Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis.
Ning S; Jorfi M
J Neurophysiol; 2019 Jul; 122(1):1-4. PubMed ID: 30864847
[TBL] [Abstract][Full Text] [Related]
14. Relevance of electroencephalogram assessment in amyloid and tau pathology in rat.
Maleysson V; Page G; Janet T; Klein RL; Haida O; Maurin A; Richard S; Champeroux P; Fauconneau B
Behav Brain Res; 2019 Feb; 359():127-134. PubMed ID: 30367970
[TBL] [Abstract][Full Text] [Related]
15. Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.
Osorio RS; Ducca EL; Wohlleber ME; Tanzi EB; Gumb T; Twumasi A; Tweardy S; Lewis C; Fischer E; Koushyk V; Cuartero-Toledo M; Sheikh MO; Pirraglia E; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Schuetz S; Varga AW; Ayappa I; Rapoport DM; de Leon MJ
Sleep; 2016 Jun; 39(6):1253-60. PubMed ID: 26951396
[TBL] [Abstract][Full Text] [Related]
16. Orexin A peptidergic system: comparative sleep behavior, morphology and population in brains between wild type and Alzheimer's disease mice.
Zhao P; You Y; Wang Z; Zhou Y; Chai G; Yan G; Jin Z; Wang Q; Sun H
Brain Struct Funct; 2022 Apr; 227(3):1051-1065. PubMed ID: 35066609
[TBL] [Abstract][Full Text] [Related]
17. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease pathogenesis: The role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes.
Havekes R; Heckman PRA; Wams EJ; Stasiukonyte N; Meerlo P; Eisel ULM
Cell Signal; 2019 Dec; 64():109420. PubMed ID: 31536750
[TBL] [Abstract][Full Text] [Related]
19. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
20. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target.
Gao F; Liu T; Tuo M; Chi S
Neurosci Lett; 2021 Nov; 765():136247. PubMed ID: 34530113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
